BACKGROUND A patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO’s ability to predict clinical response to gastrointestinal (GI) cancers.METHODS We generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma. We compared PDO response with the observed clinical response for donor patients to the same treatments.RESULTS We report an approximately 80% concordance rate between PDO and donor tumor response. Importantly, we found a profound influence of culture media on PDO phenotype, where we showed a significant difference in response to standard-of-care chemotherapies, distinct morphologies, and transcriptomes between media within the same PDO cultures.CONCLUSION While we demonstrate a high concordance rate between donor tumor and PDO, these studies also showed the important role of culture media when using PDOs to inform treatment selection and predict response across a spectrum of GI cancers.TRIAL REGISTRATION Not applicable.FUNDING The Joan F. & Richard A. Abdoo Family Fund in Colorectal Cancer Research, GI Cancer program of the Mayo Clinic Cancer Center, Mayo Clinic SPORE in Pancreatic Cancer, Center of Individualized Medicine (Mayo Clinic), Department of Laboratory Medicine and Pathology (Mayo Clinic), Incyte Pharmaceuticals and Mayo Clinic Hepatobiliary SPORE, University of Minnesota-Mayo Clinic Partnership, and the Early Therapeutic program (Department of Oncology, Mayo Clinic).
Tara L. Hogenson, Hao Xie, William J. Phillips, Merih D. Toruner, Jenny J. Li, Isaac P. Horn, Devin J. Kennedy, Luciana L. Almada, David L. Marks, Ryan M. Carr, Murat Toruner, Ashley N. Sigafoos, Amanda N. Koenig-Kappes, Rachel L.O. Olson, Ezequiel J. Tolosa, Cheng Zhang, Hu Li, Jason D. Doles, Jonathan Bleeker, Michael T. Barrett, James H. Boyum, Benjamin R. Kipp, Amit Mahipal, Joleen M. Hubbard, Temperance J. Scheffler Hanson, Gloria M. Petersen, Surendra Dasari, Ann L. Oberg, Mark J. Truty, Rondell P. Graham, Michael J. Levy, Mojun Zhu, Daniel D. Billadeau, Alex A. Adjei, Nelson Dusetti, Juan L. Iovanna, Tanios S. Bekaii-Saab, Wen Wee Ma, Martin E. Fernandez-Zapico
Title and authors | Publication | Year |
---|---|---|
Establishing Pancreatic Cancer Organoids from EUS-Guided Fine-Needle Biopsy Specimens
Wang MJ, Gao C, Huang X, Wang M, Zhang S, Gao XP, Zhong CQ, Li LY |
Cancers | 2025 |
The impact of extracellular matrix on the precision medicine utility of pancreatic cancer patient-derived organoids
Jan Lumibao, Shira R Okhovat, Kristina L Peck, Xiaoxue Lin, Kathryn Lande, Jingjing Zou, Dannielle Engle |
JCI Insight | 2024 |
Rebuilding the microenvironment of primary tumors in humans: a focus on stroma
Mun S, Lee HJ, Kim P |
Experimental & molecular medicine | 2024 |
Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma.
Desai A, Xiao AH, Choi D, Toruner MD, Walden D, Halfdanarson TR, Alberts S, McWilliams RR, Mahipal A, Ahn D, Babiker H, Stybayeva G, Revzin A, Kizilbash S, Adjei A, Bekaii-Saab T, Mansfield AS, Carr RM, Ma WW |
Cancers | 2024 |
Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development
Xiang D, He A, Zhou R, Wang Y, Xiao X, Gong T, Kang W, Lin X, Wang X, Liu L, Chen YG, Gao S, Liu Y |
Theranostics | 2024 |
XENTURION is a population-level multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients
Leto SM, Grassi E, Avolio M, Vurchio V, Cottino F, Ferri M, Zanella ER, Borgato S, Corti G, di Blasio L, Somale D, Vara-Messler M, Galimi F, Sassi F, Lupo B, Catalano I, Pinnelli M, Viviani M, Sperti L, Mellano A, Ferrero A, Zingaretti CC, Puliafito A, Primo L, Bertotti A, Trusolino L |
Nature Communications | 2024 |
Comparative Analysis of Commercial and Home-Made Media on RSPO1/S6R Axis in Organoids with Different Wnt Backgrounds: A Methodological Guide for the Selection of Intestinal Patient-Derived Organoids Culture Media.
Calafato G, Alquati C, Bernardi A, Di Paola FJ, Ricciardiello L |
International journal of molecular sciences | 2024 |
Strategic insights into the cultivation of pancreatic cancer organoids from endoscopic ultrasonography-guided biopsy tissue.
Yang JL, Zhang JF, Gu JY, Gao M, Zheng MY, Guo SX, Zhang T |
World journal of gastroenterology | 2024 |
Novel Uveal Melanoma Patient-Derived Organoid Models Recapitulate Human Disease to Support Translational Research
Dalvin LA, Andrews-Pfannkoch CM, Miley DR, Hogenson TL, Erickson SA, Malpotra S, Anderson KJ, Omer ME, Almada LL, Zhang C, Li H, Salomao DR, Shields CL, Lally SE, Malsch RM, Armitage JA, Holmes HL, Romero MF, Fautsch MP, Markovic SN, Fernandez-Zapico ME |
Investigative Ophthalmology & Visual Science | 2024 |
Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy
Taurin S, Alzahrani R, Aloraibi S, Ashi L, Alharmi R, Hassani N |
Translational Oncology | 2024 |
KRASG 12C ‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
Tapia Contreras C, Falke JD, Seifert D, Schneider C, Krauß L, Fang X, Müller D, Demirdizen E, Spitzner M, De Oliveira T, Schneeweis C, Gaedcke J, Kaulfuß S, Mirzakhani K, Wollnik B, Conrads K, Beißbarth T, Salinas G, Hügel J, Beyer N, Rheinländer S, Sax U, Wirth M, Conradi L, Reichert M, Ellenrieder V, Ströbel P, Ghadimi M, Grade M, Saur D, Hessmann E, Schneider G |
Molecular Oncology | 2024 |
Organoid‐based precision medicine in pancreatic cancer
Beutel AK, Ekizce M, Ettrich TJ, Seufferlein T, Lindenmayer J, Gout J, Kleger A |
United European Gastroenterology Journal | 2024 |
The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer
Su C, Olsen KA, Bond CE, Whitehall VL |
Cancers | 2023 |
Ultrasound-guided fine-needle aspiration/biopsy-based pancreatic organoids establishment: an alternative model for basic and preclinical research
Chen S, Wang M, Liu L, Wang G, Wang L, Zhong C, Gao C, Wu W, Li L |
Gastroenterology Report | 2023 |
Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
Alem D, Yang X, Beato F, Sarcar B, Tassielli AF, Dai R, Hogenson TL, Park MA, Jiang K, Cai J, Yuan Y, Fernandez-Zapico ME, Tan AC, Fleming JB, Xie H |
Molecular Carcinogenesis | 2023 |
Models in Pancreatic Neuroendocrine Neoplasms: Current Perspectives and Future Directions
Forsythe SD, Pu T, Andrews SG, Madigan JP, Sadowski SM |
Cancers | 2023 |
Ectopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion
Gutierrez-Ruiz OL, Johnson KM, Krueger EW, Nooren RE, Cruz-Reyes N, Heppelmann CJ, Hogenson TL, Fernandez-Zapico ME, McNiven MA, Razidlo GL |
Cell Reports | 2023 |
Role of Endoscopic Ultrasound in Diagnosis of Pancreatic Ductal Adenocarcinoma
Chatterjee A, Shah J |
Diagnostics | 2023 |
A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D'Andrea AD, Aguirre AJ, Shapiro GI, Cleary JM |
Clinical cancer research | 2023 |
Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy
Choi D, Gonzalez\u2010Suarez AM, Dumbrava MG, Medlyn M, de Hoyos\u2010Vega JM, Cichocki F, Miller JS, Ding L, Zhu M, Stybayeva G, Gaspar\u2010Maia A, Billadeau DD, Ma WW, Revzin A |
Advanced Science | 2023 |